CRYOPORT, INC. Business Combination, Acquisition Related Costs
CRYOPORT, INC. (CYRX) reported Business Combination, Acquisition Related Costs of $5.70 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2020-11-06
- CRYOPORT, INC. business combination, acquisition related costs for the quarter ending 2020-09-30 was $5.70M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 9 month |
|---|---|---|
| 2020-09-30 | $5.70M 10-Q · filed 2020-11-06 | $7.40M 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |